Cargando…

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

SIMPLE SUMMARY: There is a crucial need to improve treatment regimens in patients with recurrent endometrial cancer. Although immunotherapy treatments have shown impressive benefit in microsatellite instability-high endometrial cancer, they have been less predictable in the majority of endometrial c...

Descripción completa

Detalles Bibliográficos
Autores principales:	How, Jeffrey A., Jazaeri, Amir A., Fu, Siqing, Rodon Ahnert, Jordi, Gong, Jing, Stephen, Bettzy, Ferreira Dalla Pria, Hanna, Bhosale, Priya, Johnson, Amber, Yuan, Ying, Meric-Bernstam, Funda, Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367373/ https://www.ncbi.nlm.nih.gov/pubmed/35954359 http://dx.doi.org/10.3390/cancers14153695

Ejemplares similares

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
por: How, Jeffrey A., et al.
Publicado: (2021)

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
por: Moyers, Justin T., et al.
Publicado: (2023)

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
por: Son, Ji, et al.
Publicado: (2023)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment
por: Subbiah, Vivek, et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
por: Raghav, Kanwal P, et al.
Publicado: (2022)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Clinical next generation sequencing to identify actionable aberrations in a phase I program
por: Boland, Genevieve M., et al.
Publicado: (2015)

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
por: Livingston, J. Andrew, et al.
Publicado: (2016)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)

Author response to Cunha et al
por: Colen, Rivka R, et al.
Publicado: (2021)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

Associations between the gut microbiome and fatigue in cancer patients
por: Hajjar, Joud, et al.
Publicado: (2021)

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
por: Hahn, Andrew W, et al.
Publicado: (2020)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors
por: Lee, Minyi, et al.
Publicado: (2020)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aq3isahp2b3hltc1q35f3do4qt